Rezolute Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
30.6%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$0.70next fiscal year
Monitoring Framework
Key Performance Indicators
Phase 3 upLIFT Study Enrollment and Topline Results QuarterlyTarget: Complete enrollment and report topline results in H2 2026
Phase 2/3 Study of Ersodetug (RZ358) in Congenital Hyperinsulinism (cHI) Enrollment QuarterlyTarget: Complete enrollment by the second half of 2026, with topline data in early 2027
RZ402 Phase 2 DME Trial Progress QuarterlyTarget: Share interim results or advance clinical development in 2026
Cash Runway and Operating Cash Burn Quarterly167.9MTarget: Maintain sufficient cash to fund operations into late 2026 / early 2027
Watch Items
- FDA Regulatory Feedback on sunRIZE Phase 3 StudyTrigger: FDA independent review of comprehensive datasets and summary outcomesAction: Submit comprehensive analysis datasets and summary outcomes to the FDA following the March 2026 Type B meeting
- Phase 3 upLIFT Study Topline Readout in Tumor Hyperinsulinism (tHI)Trigger: Topline results expected in the second half of 2026Action: Monitor clinical efficacy (reduction in IV glucose infusion requirements) and safety profile to support potential regulatory filings
Research as of 19 Jun 2026